Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 4/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 4/20 | 0.37 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12497542 | 0.84 | NOS1 (0.53) | SCN4AF2PLAUKLKB1ELANE | |
| SCHEMBL17156380 | 0.83 | F2 (0.41) | F2PLAUKLKB1ELANESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL12498721 | 0.82 | NOS1 (0.52) | F2PLAUKLKB1ELANESMN1; SMN2 | |
| SCHEMBL17489137 | 0.79 | ALOX15 (0.50) | F2PLAUKLKB1ELANESMN1; SMN2 | |
| SCHEMBL3004290 | 0.76 | — | — | |
| SCHEMBL9393958 | 0.75 | F2 (0.39) | SCN4AF2PLAUKLKB1ELANE | |
| SCHEMBL6049125 | 0.74 | — | — | |
| SCHEMBL1906920 | 0.74 | — | — | |
| SCHEMBL4106091 | 0.74 | — | — | |
| SCHEMBL6685826 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2640375-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | Novartis AG (CH) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012065958-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| US-20090143440-A1 | Pyrazoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-06-04 | — | — | US | disclosed |
| EP-1682538-A4 | BIARYL LINKED HYDROXAMATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S BIO PTE LTD (SG) | 2009-05-27 | — | — | EP | disclosed |
| EP-1943241-A1 | PYRAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007051981-A1 | PYRAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2007-05-10 | — | — | WO | disclosed |
| EP-1682538-A1 | BIARYL LINKED HYDROXAMATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*Bio Pte Ltd (SG) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005040161-A1 | BIARYL LINKED HYDROXAMATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD (SG) | 2005-05-06 | — | — | WO | disclosed |
| EP-0757987-B1 | Pyrazole-carboxylic acid derivatives as plant disease control agents | NISSAN CHEMICAL IND LTD (JP) | 2000-07-19 | — | — | EP | disclosed |
| US-5955474-A | ANTIEDEMA AGENTS OR DIURETIC ANTAGONIST | SANOFI (FR) | 1999-09-21 | — | — | US | disclosed |
| EP-0699438-A2 | Use of neurotensin antagonists for the preparation of diuretic drugs | SANOFI (FR) | 1996-03-06 | — | — | EP | disclosed |
| EP-0419917-B1 | Pyrazol-3-carboxylic acid amides | BASF AG (DE) | 1994-11-17 | — | — | EP | disclosed |
| EP-0419917-A1 | Pyrazol-3-carboxylic acid amides | BASF Aktiengesellschaft (DE) | 1991-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143440-A1 | Pyrazoles Useful in the Treatment of Inflammation | ALOX15, ALOX12, ALOX15B | SCN4A 2923/4885SCN9A 3723/4885F2 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.